Z-FAST study to evaluate Femara and Zometa in postmenopausal women.(Zometa-Femara Adjuvant Synergy Trial)

2003 JAN 14 - (NewsRx.com & NewsRx.net) -- Novartis announced that it is combining two widely used drugs in a trial to evaluate bone loss associated with cancer treatment in postmenopausal women with early breast cancer.

The Novartis drugs being paired are Femara (letrozole tablets), a leading aromatase inhibitor in advanced breast cancer, and Zometa (zoledronic acid for injection), the most widely used IV bisphosphonate in treating bone complications of advanced cancer.

The study, Z-FAST (Zometa-Femara adjuvant synergy trial) is a multicenter trial designed to help address two important and unanswered clinical questions facing the breast cancer community: …